Can doxazosin inhibit the hypertension-induced changes of endocrine cells in the stomach of spontaneously hypertensive rats?

Journal of Physiology and Pharmacology

Volumn 59, Issue 1, 2008, Pages 189-201

  Kasacka, Irena ^a   Majewski, Mariusz ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Chromogranin; Doxazosin; Endocrine cells; Gastrin; Hypertension; Rat; Serotonin; Somatostatin

Indexed keywords

ANTIBODY; CHROMOGRANIN; DOXAZOSIN; EOSIN; GASTRIN; HEMATOXYLIN; HORMONE ANTIBODY; PARAFFIN; SEROTONIN; SILVER; SOMATOSTATIN; SOMATOSTATIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CELL DENSITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NEUROSECRETORY CELL; NONHUMAN; PYLORUS; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STAINING; STOMACH; STOMACH MUCOSA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; ENTEROENDOCRINE CELLS; GASTRIC MUCOSA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; PYLORUS; RATS; RATS, INBRED SHR; STOMACH;

EID: 42049117320     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Yasuda G, Hasegawa K, Kuji T, et al. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. Diabet Med 2005; 22:1394-1400.
2. Kristek F, Koprdova R, Cebova M. Long-term effects of early administered sildenafil and NO donor on the cardiovascular system of SHR. J Physiol Pharmacol 2007; 58: 33-43.
3. Izdebska E, Izdebski J, Cybulska I, Makowiecka-Ciesla M, Trzebski A. Moderate exercise training reduces arterial chemoreceptor reflex drive in mild hypertension. J Physiol Pharmacol 2006; 57 Suppl 3: 93-102.
4. Zwirska-Korczala K, Konturek SJ, Sodowski M, et al. Basal and postprandial plasma levels of PPY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome. J Physiol Pharmacol 2007; 58 Suppl 1: 13-35.
5. Kvetnoy IM, Hernandez-Yago J, Hernandez JM, Kvetnaia TV, Reiter RJ, Khavinson VK. Diffuse neuroendocrine system and mitochondrial diseases: molecular and cellular bases of pathogenesis, new approaches to diagnosis and therapy. Neuro Endocrinol Lett 2000; 21: 83-99.
6. Lundgren O. Interface between the intestinal environment and the nervous system. Gut 2004; 53: 16-18.7.
7. Baranowska B, Bik W, Baranowska-Bik A, et al. Neuroendocrine control of metabolic homeostasis in polish centenarians. J Physiol Pharmacol 2006; 57 Suppl 6: 55-61.
8. Rehfeld JF. The new biology of gastrointestinal hormones. Physiol Rev 1998; 78: 1087- 1108.
9. Grimelius L. A silver nitrate stain for alpha-2 cells in human pancreatic islets. Acta Soc Med Ups 1968; 73: 243-270.
10. Herman GE, Elfont EA. The taming of immunohistochemistry: the new era of quality control. Biotech Histochem 1991; 66: 194-199.
11. Escribano LM, Gabriel LC, Villa E, Navarro JL. Endogenous peroxidase activity in human cutaneous and adenoidal mast cells. J Histochem Cytochem 1987; 35: 213-220.
12. Bargsten G, Grube D. Serotonin storage and chromogranins: an experimental study in rat gastric endocrine cells. J Histochem Cytochem 1992; 40: 1147-1155.
13. Kasacka I, Majewski M. An immunohistochemical study of endocrine cells in the stomach of hypertensive rats. J Physiol Pharmacol 2007; 58 (in press).
14. Fletcher EC, Lesske J, Culman J, Miller CC, Unger T. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992; 20: 612-619.
15. Garcia-Rio F, Racionero MA, Pino JM, et al. Sleep apnea and hypertension. Chest 2000; 117: 1417-1425.
16. Marrone O, Riccobono L, Salvaggio A, Mirabella A, Bonanno A, Bonsignore MR. Catecholamines and blood pressure in obstructive sleep apnea syndrome. Chest 1993; 103: 722-727.
17. Rakugi H, Tabuchi Y, Nakamaru M, et al. Endothelin activates the vascular renin-angiotensin system in rat mesenteric arteries. Biochem Int 1990; 21: 867-72.
18. Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006; 57: 529-539.
19. Kvetnoi IM, Ingel IE. Hormonal function of nonendocrine cells: role of new biological phenomenon in the regulation of homeostasis. Bull Exp Biol Med 2000; 130: 1027-1030.
20. Dockray GJ. Luminal sensing in the gut: an overview. J Physiol Pharmacol 2003; 54: 9-17.
21. Dockray GJ, Varro A, Dimaline R. Gastric endocrine cells: gene expression, processing, and targeting of active products. Physiol Rev 1996; 76: 767-98.
22. Kasacka I. Quantitative characteristics of somatostatin-like cells in the stomach of uraemic rats. J Physiol Pharmacol 2006; 57: 59-71.
23. Noll T, Hempel A, Piper HM. Neuropeptide Y reduces macromolecule permeability of coronary endothelial monolayers. Am J Physiol 1996; 271: 1878-1883.
24. Hempel A, Noll T, Bach C, et al. Atrial natriuretic peptide clearance receptor participates in modulating endothelial permeability. Am J Physiol 1998; 275: 1818-1825.
25. 3H]dopamine release by neuropeptide Y in rat striatal slices. Eur J Pharmacol 1997; 321: 5-11.
26. Li Y, Anand-Srivastava MB. Inactivation of enhanced expression of G(i) proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats. Circ Res 2002; 91: 247-254.
27. Qian B, Danielsson A, el-Salhy M. Vagal regulation of the gastrointestinal neuroendocrine system. Scand J Gastroenterol 1996; 31: 529-540.
28. Qian BF, el-Salhy M, Danielsson A, Shalaby A, Axelsson H. Changes in intestinal endocrine cells in the mouse after unilateral cervical vagotomy. Histol Histopathol 1999; 14: 453-460.
29. Qian BF, el-Salhy M, Danielsson A, Shalaby A, Axelsson H. Effects of unilateral cervical vagotomy on antral endocrine cells in mouse. Histol Histopathol 1999; 14: 705-709.
30. Zdon MJ, Lewis JJ, Adrian TE, Modlin IM. Hypergastrinemia after vagotomy is not associated with decreased gastric somatostatin. Surgery 1989; 106: 1074-1080.
31. Kim T, Loh YP. Chromogranin A: a surprising link between granule biogenesis and hypertension. J Clin Invest 2005; 115: 1711-1713.
32. Faure C, Pimoule C, Arbilla S, Langer SZ, Graham D. Expression of alpha 1- adrenoceptor subtypes in rat tissues: implications for alpha 1-adrenoceptor classification. Eur J Pharmacol 1994; 268: 141-149.
33. Garcia-Sainz JA, Vazquez-Prado J, Villalobos-Molina R. Alpha 1-adrenoceptors: subtypes, signaling, and roles in health and disease. Arch Med Res 1999; 30: 449-458.
34. Zhang L, Taniguchi T, Tanaka T, Shinozuka K, Kunitomo M, Nishiyama M, Kamata K, Muramatsu I. Alpha-1 adrenoceptor up-regulation induced by prazosin but not KMD-3213 or reserpine in rats. Br J Pharmacol 2002; 135: 1757-1764.
35. Takata Y, Yoshizumi T, Ito Y, Hirota Y, Fujishima M. Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension. Angiology 1995; 46: 11-18.
36. Kario K, Schwartz JE, Pickering TG. Changes of nocturnal blood pressure dipping status in hypertensives by nighttime dosing of alpha-adrenergic blocker, doxazosin: results from the HALT study. Hypertension 2000; 35: 787-794.
37. Yasuda G, Hasegawa K, Kuji T, et al. Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. Diabet Med 2005; 22: 1394-1400.